As our current situation continues to evolve, it is critical that your out-licensing and/or financing business plans and presentations account for COVID-19. This should be communicated to prospective investors and…
Last week Reuters published an article summarizing the "virtual" biotech business model. It was a strange article, considering that this is not a new approach. Indeed, we wrote about this…
Today's issue of Institutional Investor has an interesting article on the reality of 10-year venture funds. The author presents statistics demonstrating that <10% of ten-year venture funds actually liquidate…
Mind The Gap... We're late to this party, but a really good interview of David Grainger from Index Ventures was published in July of this year. We encourage you to read…
We generally agree with the notion that many early-stage biotechs should be structured as LLCs instead of C corps. This short interview with Attorney Albert L. Sokol highlights one key…
As we read the continuing bad news regarding venture financing in biotech, we came across this bit of news from the UK: BioCity Nottingham-based CompanDX Limited, the Nottingham Trent University…
Thank goodness for Twitter. How else can one keep up with all of the news and happenings in our industry during the "slow" month of July? Here are a few…
One again, Bruce Booth published a terrific post entitled Contrarian Opportunities in Biotech Venture. The crux of the article is that while big pharma is licensing in areas such as…
The February, 2012 issue of Life Science Leader has a wide-ranging interview with G. Steven Burrill. It's an interesting, insightful read, and we can recommend the interview. Mr. Burrill makes…
Earlier this month, Keith Powell posed an interesting question: The economies of California and the UK are similar, as are the university networks. Why then, does California boast the most…